CRDF · Cardiff Oncology Inc
United States · RS rating 25 · As of 2026-10-14
| Price | 0.97 USD |
|---|---|
| 1-day change | -3.6% |
| RS rating (overall / 1M / 3M / 12M) | 25 / 7 / 86 / 12 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 23 / 6 / 22 |
| Industry group (rank) | Medical-Research Eqp/Svc (31) |
| EPS growth Q/Q | +22.2% |
| Sales growth Q/Q | +102.5% |
| Distance from 52-week high | +69.7% |
| Market cap (USD) | $114.2M |